alzheim
diseas
progress
neurodegen
dementia
elderli
character
well
defin
patholog
includ
accumul
plaqu
hyperphosphoryl
tau
ultim
form
neurofibrillari
tangl
neuron
loss
addit
hallmark
promin
inflammatori
reaction
character
presenc
reactiv
glia
associ
fibrillar
plaqu
upregul
sever
complement
protein
includ
local
synthesi
compon
observ
associ
fibrillar
plaqu
well
tangl
presenc
associ
dystroph
neurit
plaqu
tangl
indic
complement
fulli
activ
ad
vivo
observ
support
vitro
studi
demonstr
fibrillar
activ
classic
altern
complement
pathway
complement
activ
fragment
chemotact
microglia
led
hypothesi
complement
activ
trigger
fibrillar
contribut
inflammatori
reaction
play
detriment
role
progress
later
stage
alzheim
diseas
genet
pharmacolog
approach
use
investig
hypothesi
first
transgen
mous
model
ad
cross
mous
gener
appq
mous
lack
first
compon
classic
complement
pathway
observ
decreas
reactiv
glia
associ
fibrillar
amyloid
plaqu
appq
compar
app
mice
age
analyz
addit
appq
mice
show
greater
synaptophysin
syn
stain
rel
app
mice
indic
preserv
neuron
integr
second
approach
mice
treat
specif
antagonist
receptor
complement
activ
fragment
three
month
treat
anim
show
decreas
plaqu
glia
patholog
increas
syn
stain
cognit
improv
mice
mous
model
ad
develop
neurofibrillar
tangl
well
plaqu
similarli
treat
also
show
decreas
plaqu
reactiv
glia
addit
decreas
hyperphosphory
tau
result
support
hypothesi
complement
activ
play
detriment
role
ad
sinc
inhibit
classic
complement
activ
block
downstream
pathway
inhibit
interact
render
substanti
improv
patholog
behavior
anim
sinc
also
report
bind
hyperphosphoryl
tau
activ
complement
vitro
contribut
complement
activ
kinet
appear
accumul
amyloid
plaqu
phosphoryl
tau
assess
lack
differ
age
addit
caveat
use
standard
mous
model
studi
involv
complement
human
ad
report
weak
hemolyt
activ
mous
complement
basi
appar
defici
seen
vitro
assay
delin
one
possibl
consequ
vivo
would
lower
less
effici
cleavag
thu
lower
gener
proinflammatori
peptid
membran
attack
complex
compos
would
result
decreas
bystand
damag
cell
mous
system
also
decreas
proinflammatori
activ
rel
human
system
bubbnj
strain
mice
higher
complement
hemolyt
activ
measur
vitro
current
transgen
mous
ad
model
determin
paramet
translat
differ
patholog
model
backcross
n
bub
strain
bubq
develop
patholog
compar
mix
background
result
show
presenc
absenc
gener
differ
plaqu
tangl
patholog
inflammatori
respons
anim
model
interestingli
howev
detect
associ
plaqu
model
contrast
promin
deposit
transgen
model
data
indic
classic
complement
pathway
may
contribut
gener
inflamm
model
develop
patholog
slowli
model
diseas
howev
increas
patholog
observ
backcross
bub
background
rel
initi
sinc
previous
demonstr
suppress
patholog
model
receptor
antagonist
result
suggest
activ
altern
complement
pathway
presenc
cleav
enzym
may
mechan
proinflammatori
peptid
gener
model
mice
harbor
swedish
mutat
human
four
repeat
tau
mutat
knock
mutat
mix
background
gener
provid
dr
frank
laferla
uci
irvin
ca
mice
backcross
gener
bubbnj
strain
jackson
laboratori
bar
harbor
main
gener
mice
cross
knockout
mice
previous
backcross
onto
onto
bub
background
homozyg
marker
valid
pcr
andor
qpcr
test
breed
gener
respect
coloni
gener
initi
breeder
patholog
featur
origin
report
show
slower
progress
ad
patholog
origin
report
coloni
show
signific
gender
differ
patholog
seen
investig
sinc
coloni
femal
present
significantli
higher
patholog
male
age
data
report
femal
non
transgen
mice
litterm
background
use
control
maintain
breed
obtain
jackson
laboratori
arcticmut
happ
mice
obtain
dr
lennart
muck
gladston
institut
san
francisco
ca
backcross
onto
strain
jackson
laboratori
mice
anesthet
mixtur
ketaminexylazin
mgkg
perfus
pb
dissect
half
brain
immedi
frozen
dri
ice
half
fix
overnight
paraformaldehyd
immunohistochemistri
thereaft
fix
tissu
store
na
azid
use
vibratom
section
coron
um
incub
sequenti
meohtb
block
endoperoxidas
tritontb
block
non
specif
bind
correspond
primari
antibodi
control
igg
block
solut
previous
describ
primari
antibodi
detect
biotinyl
secondari
antibodi
correspond
speci
follow
abc
complex
dab
vector
burlingam
ca
immunofluoresc
stain
detect
done
speci
specif
biotinyl
antibodi
follow
jackson
west
grove
pennsylvania
dilut
sa
invitrogen
carlsbad
ca
dilut
coloc
gfap
tissu
incub
primari
antibodi
simultan
detect
biotinyl
anti
rat
antibodi
follow
gfap
label
anti
rabbit
igg
immunofluoresc
stain
use
anti
antibodi
primari
antibodi
detect
incub
correspond
biotinyl
secondari
antibodi
follow
abc
complex
final
step
nel
tsa
plu
perkin
elmer
shelton
ct
dilut
amplif
buffer
done
per
manufactur
instruct
singl
doubl
label
control
omiss
primari
antibodi
inclus
normal
igg
perform
neg
primari
antibodi
use
rabbit
polyclon
anti
mous
ugml
rat
monoclon
anti
ugml
serotec
raleigh
nc
mous
monoclon
anti
hyperphosphoryl
tau
respect
pierc
rockford
il
rat
monoclon
anti
mous
cell
scienc
rabbit
anti
mous
properdin
antibodi
three
antibodi
use
detect
rat
monoclon
anti
mous
clone
cell
scienc
canton
rabbit
polyclon
anti
human
dako
carpinteria
ca
rabbit
polyclon
anti
human
dako
rat
monoclon
anti
mous
cell
scienc
clone
specif
recogn
cleav
nativ
fibrillar
stain
thioflavin
previous
describ
immunostain
observ
zeiss
invert
microscop
carl
zeiss
thornwood
ny
imag
acquir
zeiss
axiocam
highresolut
digit
color
camera
pixel
use
axiovis
softwar
softwar
carl
zeiss
use
analyz
digit
imag
percent
immunoposit
area
field
area
immunoposit
areatot
imag
area
determin
marker
studi
averag
imag
subiculum
area
section
per
anim
digit
imag
obtain
use
set
segment
paramet
constant
within
rang
per
given
marker
experi
mean
valu
field
area
marker
anim
averag
per
genotyp
group
number
anim
per
group
indic
figur
legend
data
analyz
use
singl
anova
statist
analysi
stain
anim
trial
compar
imag
analysi
done
simultan
per
given
marker
total
rna
pulver
frozen
cortic
mg
hippocampi
mg
extract
use
illustra
rnaspin
mini
kit
ge
healthcar
life
scienc
piscataway
nj
follow
manufactur
instruct
cdna
synthesi
carri
ng
total
rna
oligo
dt
primer
unit
rnaseout
unit
mmlv
revers
transcriptas
rt
invitrogen
carlsbad
ca
accord
manufactur
protocol
quantit
pcr
perform
use
icycl
iq
softwar
biorad
hercul
ca
briefli
amplif
conduct
volum
use
maxima
sybrgreen
master
mix
fermenta
glen
burni
md
ng
templat
cdna
forward
revers
genespecif
primer
primer
agaccgacctcattttcttctg
acccgactttgttctttggtg
tacatcagcacctcacaagca
agaaacagtccagcccatact
cactcacctgctgctactcattc
ccattccttcttggggtca
aggagacttcacagaggatacca
catttccacgatttcccagag
ggtgttcatccattctctacc
gagccataatcccctttctaa
gapdhf
aactcccactcttccaccttc
gapdhr
ggtccagggtttcttactcctt
design
use
tool
http
obtain
eurofin
mwg
operon
huntsvil
al
rt
omit
neg
control
folddiffer
target
gene
cdna
rel
gapdh
endogen
control
determin
use
rel
quantif
method
follow
folddiffer
cttarget
ctgapdh
ct
valu
defin
number
cycl
fluoresc
signal
detect
result
repres
individu
scatter
dot
plot
mean
sem
folddiffer
genotyp
group
compar
twotail
ttest
bonferroni
post
hoc
test
alpha
error
pearson
rank
correl
coeffici
differ
consid
signific
p
kinet
progress
plaqu
deposit
activ
glia
tangl
patholog
compar
backcross
knock
assess
anim
month
age
permit
comparison
multipl
stage
plaqu
format
coloni
mice
plaqu
deposit
seen
anim
signific
number
plaqu
subiculum
area
hippocampu
deposit
fibrillar
plaqu
detect
thioflavin
stain
label
fibrillar
amyloid
assess
imag
analysi
subiculum
area
hippocampu
area
patholog
start
model
vs
group
shown
figur
signific
differ
amount
fibrillar
plaqu
seen
age
similarli
total
amyloid
immunostain
use
antibodi
show
differ
group
data
shown
studi
perform
use
bub
background
differ
amount
plaqu
seen
age
studi
presenc
absenc
figur
howev
bub
background
higher
thioflavin
stain
mix
background
fold
greater
amount
statist
signific
p
contrast
previou
comparison
mice
delet
affect
level
immunoreact
activ
microglia
seen
around
plaqu
model
figur
model
bub
background
figur
howev
seen
thioflavin
result
trend
increas
stain
observ
compar
differ
statist
signific
p
variabl
patholog
marker
among
individu
anim
group
age
consider
seen
se
even
among
litterm
suggest
might
due
genet
factor
variabl
particularli
evid
microglia
reactiv
group
anim
display
littl
clear
increas
microgli
reactiv
stain
parallel
increas
seen
thioflavin
plaqu
howev
astrocyt
label
gfap
surround
plaqu
found
level
correspond
rel
thioflavin
load
data
shown
reason
variabl
microgli
reactiv
observ
current
unknown
model
develop
plaqu
patholog
also
accumul
neurofibrillari
tangl
contain
hyperphosphoryl
tau
immunostain
imag
analysi
antibodi
phosphotau
show
differ
amount
phosphoryl
tau
figur
figur
age
test
indic
lack
alter
amount
tau
phosphoryl
progress
neurofibrillari
tangl
howev
importantli
trend
increas
reactiv
bub
background
rel
reach
statist
signific
vs
group
p
evid
support
hypothesi
complement
activ
fibril
occur
ad
tenner
fonseca
activ
might
part
respons
recruit
activ
glia
gener
inflammatori
environ
area
plaqu
enhanc
neuropatholog
sever
transgen
model
ad
complement
factor
shown
associ
plaqu
model
develop
plaqu
patholog
earli
age
associ
plaqu
first
thioflavin
plaqu
develop
around
increas
age
data
shown
strongli
coloc
thioflavin
figur
left
model
also
associ
thioflavin
plaqu
figur
middl
surprisingli
neither
figur
right
bub
background
data
shown
show
detect
level
coloc
plaqu
immunostain
antibodi
recogn
cleavag
fragment
show
present
model
figur
top
coloc
thioflavin
figur
top
inset
previous
report
deposit
plaqu
mice
also
express
oligodendrocyt
figur
middl
earli
undetect
mice
age
contrast
detect
plaqu
model
even
advanc
age
figur
bottom
bub
high
complement
hemolyt
activ
strain
data
shown
immunoreact
test
use
two
monoclon
antibodi
anti
mous
antibodi
clone
recogn
intact
cleav
fragment
anti
mous
clone
specif
cleav
fragment
two
polyclon
anti
human
antibodi
react
either
antibodi
antibodi
nativ
cleav
molecul
result
immunohistochem
analysi
summar
tabl
reactiv
detect
subpopul
astrocyt
associ
plaqu
shown
polyclon
anti
human
figur
data
shown
monoclon
anti
mous
clone
figur
data
shown
consist
known
synthesi
astrocyt
injur
inflammatori
environ
mice
younger
age
antibodi
stain
astrocyt
later
age
plaqu
also
label
data
shown
stain
astrocyt
less
promin
anti
human
polyclon
antibodi
also
show
reactiv
associ
plaqu
model
older
age
figur
suggest
presenc
activ
fragment
sinc
contain
thioester
form
coval
bind
activ
fibrillar
amyloid
contrast
polyclon
anti
human
antibodi
label
astrocyt
surround
plaqu
data
shown
figur
similar
associ
plaqu
detect
either
data
shown
antibodi
figur
monoclon
react
activatedcleav
stain
plaqu
data
shown
although
reactiv
detect
demonstr
differenti
plaqu
associ
complement
compon
strain
react
similarli
anti
antibodi
data
shown
sinc
activ
detect
plaqu
mice
antibodi
avail
previou
report
demonstr
decreas
patholog
follow
treatment
antagonist
look
presenc
properdin
posit
regul
altern
pathway
evid
altern
pathway
activ
mice
use
anti
mous
properdin
antibodi
properdin
reactiv
clearli
present
associ
plaqu
occasion
astrocyt
stain
figur
figur
well
arc
data
shown
model
properdin
stain
also
observ
figur
brain
data
shown
stain
detect
nontransgen
litterm
control
figur
data
consist
altern
pathway
activ
well
arc
mous
model
express
inflammatori
gene
transcript
cortex
hippocampu
old
nontransgen
bub
bubq
control
assess
qrtpcr
figur
clearli
detect
increas
transcript
detect
hippocampu
rel
nontransgen
bub
mice
figur
specif
foldincreas
p
respect
gene
express
detect
vs
bub
nontransgen
mice
increas
seen
p
respect
compar
bubq
increas
transcript
level
rel
bub
p
increas
compar
bubq
p
howev
statist
signific
differ
knock
suffici
anim
figur
agreement
patholog
result
differ
detect
cortex
data
shown
correl
littl
patholog
cortex
mice
age
patholog
predominantli
subiculum
area
hippocampu
anim
signific
differ
mrna
level
identifi
either
region
brain
data
shown
anim
test
comparison
transcript
express
level
immunohistochem
reactiv
gener
marker
microgli
reactiv
show
trend
toward
posit
correl
express
elev
transcript
although
reach
signific
case
p
figur
presenc
complement
compon
indic
inflamm
ad
brain
suggest
complement
activ
may
contribut
progress
ad
novel
therapeut
target
vitro
data
demonstr
abil
fibrillar
activ
classic
altern
pathway
consist
complement
pathway
activ
fibrillar
amyloid
plaqu
vivo
previou
public
treatment
mice
receptor
antagonist
proinflammatori
peptid
gener
result
complement
activ
show
mark
decreas
amyloid
plaqu
hyperphosphoryl
tau
patholog
present
studi
contribut
complement
patholog
defin
model
elimin
classic
complement
pathway
activ
mice
first
bred
gener
mice
convers
enhanc
complement
activ
backcross
gener
bub
background
strain
higher
level
serum
complement
hemolyt
activ
differ
thioflavin
plaqu
reactiv
glia
hyperphosphoryl
tau
select
inflammatori
marker
detect
suffici
defici
mice
either
background
contrast
previou
studi
lack
shown
reduc
gliosi
increas
neuron
integr
consist
lack
patholog
earli
compon
classic
complement
pathway
associ
plaqu
sharp
contrast
model
figur
therefor
posit
effect
specif
antagonist
suppress
patholog
anim
suggest
either
altern
pathway
complement
activ
predomin
suffici
mechan
anim
model
altern
pathway
independ
newli
describ
enzymat
cleavag
may
sourc
contribut
patholog
mice
protect
effect
independ
effect
presenc
properdin
altern
complement
pathway
compon
stabil
convertas
well
initi
altern
pathway
activ
associ
amyloid
plaqu
well
anim
support
possibl
altern
pathway
activ
ad
model
howev
addit
contribut
gener
rule
point
role
activ
fragment
complement
mani
inflammatori
disord
includ
neurodegener
well
document
review
abrog
ad
patholog
model
backcross
defici
fvb
strain
damorrissett
phd
dissert
uci
well
delay
amyloid
accumul
mice
contain
human
app
gene
promot
support
though
prove
contribut
possibl
inhibit
receptor
close
homolog
screen
inhibit
differ
receptor
includ
ion
channel
two
transport
protein
shown
exert
inhibit
receptor
minimum
fold
higher
concentr
inhibit
treatment
mice
effect
dampen
leukocyt
migrat
cn
respons
intracrani
inocul
neurotroph
coronaviru
telan
uc
irvin
person
commun
emphas
varieti
select
chemotact
inflamm
induc
mechan
avail
inhibit
antagonist
second
major
find
studi
thioflavin
posit
plaqu
glial
accumul
detect
earlier
approxim
month
mice
rel
figur
consist
possibl
greater
gener
detriment
bub
background
sinc
evid
associ
plaqu
bub
similar
mix
background
greater
altern
pathway
complement
activ
greater
cleavag
lead
higher
gener
bub
may
basi
acceler
patholog
although
stabli
bound
plaqu
detect
possibl
low
level
altern
pathway
activ
could
occur
amplif
highli
regul
complement
regulatori
protein
crri
previous
shown
present
high
level
mice
result
low
surfac
bound
may
difficult
detect
antibodi
use
data
result
studi
us
other
suggest
role
complement
ad
complex
evid
detriment
benefici
function
exampl
transgen
express
murin
complement
inhibitor
crri
gener
defici
app
mice
result
enhanc
patholog
mous
model
suggest
protect
contribut
complement
possibl
due
opson
effect
amyloid
cellular
debri
miss
classic
altern
pathway
block
inhibit
delet
protect
role
also
consist
recent
report
demonstr
correl
induct
earli
compon
complement
suppress
deposit
ad
mous
model
howev
delet
model
ad
support
detriment
role
complement
activ
sinc
mice
show
less
reactiv
glia
surround
plaqu
increas
synaptophysin
protect
given
lack
thu
lack
classic
pathway
complement
activ
substanti
complet
suggest
altern
pathway
andor
non
complement
mediat
event
contribut
inflammatori
reaction
around
plaqu
deposit
plaqu
absenc
demonstr
altern
pathway
activ
mice
presenc
properdin
plaqu
model
assess
indic
either
complement
pathway
activ
ad
mice
first
transgen
model
ad
earli
compon
classic
complement
pathway
detect
associ
thioflavin
posit
plaqu
robust
deposit
mice
mice
plaqu
demonstr
addit
mous
model
cerebr
microvascular
amyloid
show
increas
area
fibrillar
amyloid
deposit
rule
possibl
transit
bind
thu
limit
activ
classic
complement
pathway
plaqu
increas
plaqu
bind
complement
regul
known
bind
plaqu
ad
brain
case
possibl
complement
pathway
robust
provid
plausibl
explan
progress
patholog
faster
strain
similarli
acceler
progress
patholog
bub
background
consist
role
complement
determin
rate
progress
diseas
differ
convertas
involv
classic
altern
pathway
andor
balanc
pathway
might
contribut
differ
extent
downstream
activ
gener
result
patholog
model
potenti
polymorph
associ
human
ad
also
suggest
point
control
complement
activ
sinc
critic
regul
convertas
activ
human
remain
investig
interpret
immunohistochem
data
assess
presenc
inflammatori
diseas
model
requir
understand
variou
form
recogn
antibodi
use
shown
synthes
astrocyt
microglia
cultur
brain
tissu
situ
hybrid
neurodegen
diseas
injuri
inflamm
report
associ
nativ
activ
differ
among
mous
model
neurodegener
exampl
plaqu
label
differ
level
astrocyt
label
observ
model
polyclon
anti
antibodi
weak
absent
plaqu
stain
mice
report
antibodi
polyclon
anti
human
antibodi
label
astrocyt
probabl
via
epitop
expos
intact
model
addit
monoclon
anti
antibodi
clone
recogn
intact
label
astrocyt
mice
suggest
newli
synthes
uncleav
consist
identif
acut
phase
protein
polyclon
antibodi
recogn
region
within
also
dissoci
thioester
surfac
bound
upon
second
cleavag
factor
label
mainli
astrocyt
three
model
lack
astrocyt
label
anti
recogn
cleav
support
conclus
astrocyt
label
model
repres
nativ
uncleav
importantli
activ
neoepitop
detect
monoclon
antibodi
associ
plaqu
model
plaqu
plaqu
also
stain
polyclon
anti
antibodi
like
reflect
reactiv
activ
cleav
plaqu
overal
result
consist
differenti
activ
mous
model
note
consist
observ
astrocyt
label
antibodi
test
except
specif
cleav
three
mous
model
anoth
murin
model
neurodegener
report
exclus
microglia
conclus
substanti
evid
show
strongli
associ
fibrillar
plaqu
human
ad
brain
syndrom
ad
even
earli
stage
diseas
correl
appear
fibrillar
amyloid
complement
protein
altern
pathway
also
detect
associ
plaqu
human
diseas
product
complement
factor
brain
cell
presenc
termin
complement
membranolyt
complex
detect
plaqu
tangl
human
ad
provid
evid
complement
present
fulli
activ
ad
brain
therefor
might
contribut
enhanc
neurodegener
later
stage
diseas
fibrillar
plaqu
present
mous
model
ad
exhibit
degre
mani
patholog
featur
ad
howev
absenc
definit
evid
late
complement
factor
andor
differ
ratio
complement
compon
complement
inhibitor
ad
ad
anim
model
report
suggest
might
quantit
compar
complement
activ
mous
model
human
ad
presenc
properdin
mous
model
ad
provid
evid
activ
altern
complement
pathway
consist
benefit
demonstr
well
mice
treatment
antagonist
proinflammatori
receptor
nevertheless
develop
new
mous
model
close
mimic
human
system
aspect
diseas
improv
abil
assess
contribut
complement
ad
neuropatholog
defin
target
like
promot
benefici
effect
andor
prevent
detriment
activ
aid
develop
treatment
devast
human
diseas
author
declar
compet
interest
mif
carri
part
ihc
experiment
work
statist
analysi
prepar
figur
draft
manuscript
shc
gener
genotyp
anim
use
studi
process
tissu
perform
ihc
experi
statist
analysi
ab
process
tissu
use
perform
ihc
experi
contribut
analysi
yk
provid
anti
properdin
antibodi
design
ihc
experi
meb
design
analyz
qpcr
experi
contribut
manuscript
dgp
perform
qpcr
experi
contribut
analysi
ajt
design
studi
contribut
analysi
data
prepar
manuscript
author
read
approv
final
manuscript
